405 related articles for article (PubMed ID: 33246008)
1. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus.
Blomdahl J; Nasr P; Ekstedt M; Kechagias S
Metabolism; 2021 Feb; 115():154439. PubMed ID: 33246008
[TBL] [Abstract][Full Text] [Related]
2. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease.
Hagström H; Nasr P; Ekstedt M; Kechagias S; Önnerhag K; Nilsson E; Rorsman F; Sheikhi R; Marschall HU; Hultcrantz R; Stål P
Scand J Gastroenterol; 2017 Feb; 52(2):159-165. PubMed ID: 27650916
[TBL] [Abstract][Full Text] [Related]
3. Moderate alcohol consumption is associated with significant fibrosis progression in NAFLD.
Blomdahl J; Nasr P; Ekstedt M; Kechagias S
Hepatol Commun; 2023 Jan; 7(1):e0003. PubMed ID: 36633482
[TBL] [Abstract][Full Text] [Related]
4. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease.
Mitchell T; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Ching H; Hamdorf J; Adams LA
Am J Gastroenterol; 2018 Oct; 113(10):1484-1493. PubMed ID: 29899440
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver disease.
Alkayyali T; Qutranji L; Kaya E; Bakir A; Yilmaz Y
Acta Diabetol; 2020 May; 57(5):613-618. PubMed ID: 31897769
[TBL] [Abstract][Full Text] [Related]
6. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes.
Aller de la Fuente R; Mora Cuadrado N; Tafur C; López Gómez JJ; Gómez de la Cuesta S; García Sánchez MC; Antolin Melero B; de Luis Román DA
Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(6):354-360. PubMed ID: 29477355
[TBL] [Abstract][Full Text] [Related]
7. Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus.
Chen K; Sng WK; Quah JH; Liu J; Chong BY; Lee HK; Wang XF; Tan NC; Chang PE; Tan HC; Bee YM; Goh GBB
PLoS One; 2020; 15(8):e0236977. PubMed ID: 32822391
[TBL] [Abstract][Full Text] [Related]
8. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
Ekstedt M; Franzén LE; Holmqvist M; Bendtsen P; Mathiesen UL; Bodemar G; Kechagias S
Scand J Gastroenterol; 2009; 44(3):366-74. PubMed ID: 19016382
[TBL] [Abstract][Full Text] [Related]
9. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus.
Lee H; Kim G; Choi YJ; Huh BW; Lee BW; Kang ES; Cha BS; Lee EJ; Lee YH; Huh KB
Diabetes Metab J; 2020 Apr; 44(2):267-276. PubMed ID: 30877708
[TBL] [Abstract][Full Text] [Related]
10. Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease.
Patel PJ; Smith D; Connor JP; Horsfall LU; Hayward KL; Hossain F; Williams S; Johnson T; Stuart KA; Brown NN; Saad N; Clouston AD; Irvine KM; Russell AW; Valery PC; Powell EE
Can J Gastroenterol Hepatol; 2017; 2017():7927685. PubMed ID: 29226116
[TBL] [Abstract][Full Text] [Related]
11. Association between serum interleukin (IL)-12 level and severity of non-alcoholic fatty liver disease (NAFLD).
Darmadi D; Ruslie RH
Rom J Intern Med; 2021 Mar; 59(1):66-72. PubMed ID: 33055315
[No Abstract] [Full Text] [Related]
12. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis.
Kimura T; Tanaka N; Fujimori N; Sugiura A; Yamazaki T; Joshita S; Komatsu M; Umemura T; Matsumoto A; Tanaka E
World J Gastroenterol; 2018 Apr; 24(13):1440-1450. PubMed ID: 29632425
[TBL] [Abstract][Full Text] [Related]
13. Increased severity of liver fat content and liver fibrosis in non-alcoholic fatty liver disease correlate with epicardial fat volume in type 2 diabetes: A prospective study.
Brouha SS; Nguyen P; Bettencourt R; Sirlin CB; Loomba R
Eur Radiol; 2018 Apr; 28(4):1345-1355. PubMed ID: 29058029
[TBL] [Abstract][Full Text] [Related]
14. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease.
Bertot LC; Jeffrey GP; de Boer B; MacQuillan G; Garas G; Chin J; Huang Y; Adams LA
Liver Int; 2018 Oct; 38(10):1793-1802. PubMed ID: 29575516
[TBL] [Abstract][Full Text] [Related]
15. Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease.
Kashiwagi K; Yamaguchi A; Shiba S; Taniki N; Inoue N; Takaishi H; Iwao Y; Kanai T
Alcohol; 2020 Dec; 89():1-7. PubMed ID: 32738385
[TBL] [Abstract][Full Text] [Related]
16. C-peptide is associated with NAFLD inflammatory and fibrotic progression in type 2 diabetes.
Wang N; Wang Y; Zhang W; Chen Y; Chen X; Wang C; Li Q; Chen C; Jiang B; Lu Y
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3210. PubMed ID: 31351021
[TBL] [Abstract][Full Text] [Related]
17. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
Johnston MP; Patel J; Byrne CD
Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
[TBL] [Abstract][Full Text] [Related]
18. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
[TBL] [Abstract][Full Text] [Related]
19. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
[TBL] [Abstract][Full Text] [Related]
20. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
